Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group

Paula CramerDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, GermanyCorrespondence[email protected]

Anna-Maria FinkDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany

Raymonde BuschTechnical University, Institute for Medical Statistics and Epidemiology, Munich, Germany

Barbara EichhorstDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany

Clemens-Martin WendtnerDepartment of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany

Natali PflugDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany

Petra LangerbeinsDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany

Jasmin BahloDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany

Valentin GoedeDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany

Friederike SchubertDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany

Hartmut DöhnerDepartment III of Internal Medicine, University Hospital Ulm, Ulm, Germany

Stephan StilgenbauerDepartment III of Internal Medicine, University Hospital Ulm, Ulm, Germany

Peter DregerDepartment V of Medicine, University of Heidelberg, Heidelberg, Germany

Michael KnebaDepartment II of Internal Medicine, University Hospital Schleswig-Holstein, Kiel, Germany

Sebastian BöttcherDepartment II of Internal Medicine, University Hospital Schleswig-Holstein, Kiel, Germany

Jiri MayerDepartment of Hemato-Oncology, University Hospital Brno, Brno, Czech Republic

Michael HallekDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany

Kirsten FischerDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany

show all

Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group

Supplementary Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group

Supplementary Material

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date